Breaking Finance News

Piper Jaffray downgraded Vitae Pharmaceuticals (NASDAQ:VTAE) from Overweight to Neutral in a statement released earlier today.

Showing a price of $20.85, Vitae Pharmaceuticals (NASDAQ:VTAE) traded 0.14% higher on the day. With the last stock price close up 139.29% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.01% over the same time period. The company has recorded a 50-day average of $9.66 and a two hundred day average of $8.73. Volume of trade was down over the average, with 878,811 shares of VTAE changing hands under the typical 950,048

Piper Jaffray has downgraded Vitae Pharmaceuticals (NASDAQ:VTAE) from Overweight to Neutral in a report released on 9/20/2016.

Performance Chart

Vitae Pharmaceuticals (NASDAQ:VTAE)

Vitae Pharmaceuticals has 52 week low of $4.08 and a one year high of $20.97 and has a market cap of $0.

A total of 5 analysts have released a research note on Vitae Pharmaceuticals. Three equity analysts rating the stock a strong buy, 2 firms rating the stock a buy, 0 brokerages rating the company a hold, 0 brokers rating the stock a underperform, and finally zero analysts rating the stock a sell with a consensus target price of $16.60.

Brief Synopsis About Vitae Pharmaceuticals (NASDAQ:VTAE)

Vitae Pharmaceuticals, Inc. is a biotechnology company. The Company is focused on discovering and developing small molecule drugs for diseases. It is engaged in developing a portfolio of product candidates through Contour, its structure-based drug discovery platform. The Company's product candidates include VTP- 43742 for the treatment of psoriasis, as well as multiple other autoimmune disorders. The Company completed approximately two Phase I studies with VTP-43742. Its VTP-38543, a second product candidate is in a Phase IIa proof-of-concept clinical trial for the treatment of atopic dermatitis. Its VTP-36951 is for the treatment and prevention of Alzheimer's disease, or Alzheimer's. VTP-43742, the Company's wholly owned clinical candidate in an on-going Phase IIa proof-of-concept trial in psoriasis, is an orally active small molecule inhibitor of Retinoic acid-receptor (RAR)-Related Orphan Receptor gamma-t (RORgt) activity for the treatment of various autoimmune disorders.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.